Biotricity Inc. (BTCY)

[BillyBahama]

The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few subsectors have benefitted more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction. They're doing $400M in annual sales, and their stock has climbed from trough lows at $2.50 in 2013 to $65 in just 5 years.
•Biotricity ($BTCY) is a small monitoring company with an attractive valuation compared to its bigger peers, entering the market just after their first FDA clearance. The stock is near 52-week lows after post-approval blues and could be rebounding in 2019 as this product launch goes full steam. It doesn't take much to demonstrate traction with a great device in this huge market, and with the right execution and sales figures coming, $BTCY could look like BEAT at $2.50 five years ago.